Herman Schreuder

This inventor holds 25 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Sanofi-A Ventis Deutschland Gmbh, Aventis Pharma Deutschland, Gmbh. Active years: 2003-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Herman Schreuder. Retrieved from https://idiyas.com/inventor/herman-schreuder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 5)

% Patents Active = 16.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 10)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 37(Granted Patents)

Location History:

Hofheim-Lorsbach, DE (2003 - 2010)
Hofheim, DE (2011 - 2012)
Franfurt am Main, DE (2013)
Frankfurt-am-Main, DE (2013 - 2017)

Company Filing History:

Sanofi-A Ventis Deutschland Gmbh

patents

3 out of 330

Aventis Pharma Deutschland, Gmbh

Years Active: 2003-2017

Loading Chart...

Areas of Expertise:

Pharmaceuticals

TAFIa Inhibitors

Anticoagulants

Urea Derivatives

Biaryl Derivatives

Thiazoloamino Derivatives

Propionic Acid Derivatives

Isoquinolin Derivatives

Factor IXa Inhibitors

Factor Xa Inhibitors

Antithrombotic Activity

Sulfamide Derivatives

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9751858 - 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2017-09-05),

2. 9688645 - Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa (2017-06-27),

3. 9353068 - 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2016-05-31),

4. 9309207 - Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa (2016-04-12),

5. 9199947 - Biaryl-propionic acid derivatives and their use as pharmaceuticals (2015-12-01),

6. 9174952 - Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals (2015-11-03),

7. 9150526 - Biaryl-propionic acid derivatives and their use as pharmaceuticals (2015-10-06),

8. 9126955 - Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa (2015-09-08),

9. 9120783 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2015-09-01),

10. 9029559 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2015-05-12),

11. 8962671 - Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2015-02-24),

12. 8722655 - Macrocyclic urea and sulfamide derivatives as inhibitors of tafia (2014-05-13),

13. 8669370 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2014-03-11),

14. 8664257 - Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2014-03-04),

15. 8580777 - Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa (2013-11-12),

Title: **Herman Schreuder: Innovator in Pharmaceutical Patents**

Introduction

Herman Schreuder is a prolific inventor based in Frankfurt am Main, Germany, holding an impressive portfolio of 25 patents. His work primarily revolves around innovative pharmaceutical compounds that offer significant therapeutic benefits in the treatment of various diseases.

Latest Patents

Two of his most recent patents showcase his commitment to advancing medical science. The first innovative patent involves 3-heteroaroylamino-propionic acid derivatives, which are recognized for their potential as valuable pharmaceutical active compounds. These compounds are known to inhibit the protease cathepsin A, making them suitable for treating conditions such as atherosclerosis, heart failure, renal and liver diseases, as well as other inflammatory diseases. This patent details not only the chemical formulation but also the processes for preparing these compounds and their applications in pharmaceutical compositions.

The second patent focuses on macrocyclic urea and sulfamide derivatives, which serve as inhibitors of the thrombin-activable fibrinolysis inhibitor (TAFIa). The compounds outlined in this patent are intended for the production of medicaments aimed at the prophylaxis and treatment of disorders related to thromboses, embolisms, hypercoagulability, and fibrotic changes.

Career Highlights

Herman Schreuder has made significant contributions to the pharmaceutical field through his tenure at renowned companies such as Sanofi and Sanofi-Aventis Deutschland GmbH. His work at these institutions has bolstered his ability to develop innovative solutions to pressing health issues.

Collaborations

Throughout his career, Schreuder has collaborated with notable professionals in the field, including Sven Ruf and Thorsten Sadowski. These partnerships have further enhanced the development and implementation of his patented inventions, promoting collaborative innovation in the industry.

Conclusion

With a diverse range of patents and a robust career in pharmaceutical innovations, Herman Schreuder stands out as an influential inventor in his field. His contributions not only reflect his dedication to improving healthcare but also highlight the importance of creative thinking in addressing complex medical challenges.

Profile summary based on public USPTO records.